BioCardia (BCDA) Competitors $1.87 -0.01 (-0.53%) Closing price 03:59 PM EasternExtended Trading$1.89 +0.02 (+1.28%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. COEP, ACRV, CALC, PLUR, JSPR, OVID, STTK, ALXO, FGEN, and PEPGShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Coeptis Therapeutics (COEP), Acrivon Therapeutics (ACRV), CalciMedica (CALC), Pluri (PLUR), Jasper Therapeutics (JSPR), Ovid Therapeutics (OVID), Shattuck Labs (STTK), ALX Oncology (ALXO), FibroGen (FGEN), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Its Competitors Coeptis Therapeutics Acrivon Therapeutics CalciMedica Pluri Jasper Therapeutics Ovid Therapeutics Shattuck Labs ALX Oncology FibroGen PepGen BioCardia (NASDAQ:BCDA) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Which has more risk and volatility, BCDA or COEP? BioCardia has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Do insiders and institutionals believe in BCDA or COEP? 20.6% of BioCardia shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 20.0% of BioCardia shares are owned by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate BCDA or COEP? BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 1,236.90%. Given BioCardia's stronger consensus rating and higher probable upside, equities research analysts plainly believe BioCardia is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BCDA or COEP more profitable? Coeptis Therapeutics' return on equity of -201.73% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets BioCardiaN/A -19,117.42% -246.92% Coeptis Therapeutics N/A -201.73%-108.46% Which has preferable earnings and valuation, BCDA or COEP? BioCardia has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$60K180.77-$7.95M-$1.85-1.01Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.34 Does the media favor BCDA or COEP? In the previous week, BioCardia had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 2 mentions for Coeptis Therapeutics. BioCardia's average media sentiment score of 0.29 beat Coeptis Therapeutics' score of 0.04 indicating that BioCardia is being referred to more favorably in the media. Company Overall Sentiment BioCardia Neutral Coeptis Therapeutics Neutral SummaryBioCardia beats Coeptis Therapeutics on 12 of the 15 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.91M$3.06B$5.75B$9.64BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-1.0120.6130.7825.12Price / Sales180.77360.20458.48157.26Price / CashN/A41.5625.2228.45Price / Book-5.679.509.365.94Net Income-$7.95M-$54.72M$3.26B$265.56M7 Day Performance7.47%2.39%1.83%0.95%1 Month Performance-16.14%4.60%3.69%2.47%1 Year Performance-53.25%9.11%28.88%20.24% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.6254 of 5 stars$1.87-0.5%$25.00+1,236.9%-43.4%$10.91M$60K-1.0140Short Interest ↓COEPCoeptis Therapeutics0.5216 of 5 stars$11.06-0.9%N/A+262.8%$39.21MN/A-1.912Earnings ReportShort Interest ↑ACRVAcrivon Therapeutics2.6886 of 5 stars$1.23-0.8%$17.71+1,340.2%-81.7%$38.88MN/A-0.5558Earnings ReportAnalyst RevisionCALCCalciMedica3.3582 of 5 stars$2.76+0.7%$16.00+479.7%-29.8%$38.28MN/A-1.7730News CoverageEarnings ReportShort Interest ↓Gap UpPLURPluri2.2495 of 5 stars$4.55-5.6%$12.00+163.7%-15.3%$37.91M$330K-0.82150Negative NewsShort Interest ↑Gap UpJSPRJasper Therapeutics2.9111 of 5 stars$2.63+7.3%$29.75+1,031.2%-83.8%$36.80MN/A-0.5020Earnings ReportAnalyst RevisionGap UpOVIDOvid Therapeutics4.4133 of 5 stars$0.56+7.9%$3.10+457.9%-17.7%$36.61M$570K-1.5960Trending NewsEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap DownSTTKShattuck Labs3.5244 of 5 stars$0.74-2.3%$7.50+914.6%-69.6%$36.23M$5.72M-0.53100News CoverageEarnings ReportAnalyst RevisionALXOALX Oncology2.8616 of 5 stars$0.61-9.2%$3.30+437.0%-61.8%$36.14MN/A-0.2540News CoverageEarnings ReportGap DownFGENFibroGen4.6039 of 5 stars$8.37-3.9%$43.00+413.7%+23.7%$35.20M$29.62M-3.35570News CoverageAnalyst DowngradeGap UpHigh Trading VolumePEPGPepGen3.1974 of 5 stars$1.01-5.6%$7.67+659.1%-86.2%$35.10MN/A-0.3430Gap Up Related Companies and Tools Related Companies COEP Alternatives ACRV Alternatives CALC Alternatives PLUR Alternatives JSPR Alternatives OVID Alternatives STTK Alternatives ALXO Alternatives FGEN Alternatives PEPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access